Abstract: This invention describes the novel use of alkyl, alkoxyl, halogenyl, or hydroxy substituted dicinnamoylquinides as therapeutic agents for enhancing adenosine levels in the brain and peripheral organs. These agents are particularly useful in treating human diseases or conditions that benefit from acute or chronic elevated levels of adenosine, such as reperfusion injury, coronary or cerebral ischemia, coronary vasoconstriction, paroxysmal supraventricular tachycardia, hypertension, wound healing, diabetes, inflammation, or sleep disturbances. They can also be used to protect normal cells from chemotoxicity in patients undergoing cancer therapy, and reverse the behavioral effects of caffeine intake.

Abstract: This invention describes the novel use of alkyl, alkoxyl, halogenyl, or hydroxy substituted dicinnamoylquinides as therapeutic agents for enhancing adenosine levels in the brain and peripheral organs. These agents are particularly useful in treating human diseases or conditions that benefit from acute or chronic elevated levels of adenosine, such as reperfusion injury, coronary or cerebral ischemia, coronary vasoconstriction, paroxysmal supraventricular tachycardia, hypertension, wound healing, diabetes, inflammation, or sleep disturbances. They can also be used to protect normal cells from chemotoxicity in patients undergoing cancer therapy, and reverse the behavioral effects of caffeine intake.

Abstract: This invention provides compounds of the formula I ##STR1## wherein, R.sup.1, R.sup.2, and R.sup.3 are independently ?a first halogen atom,! fluorine, chlorine, bromine, iodine, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, or alkynoxy, wherein R.sup.2 and R.sup.3 can also independently be H, wherein at least one of R.sup.1, R.sup.2, and R.sup.3 is ?a second halogen atom! fluorine, bromine, iodine or is substituted with ?a second halogen atom,! fluorine, bromine or iodine and R.sup.4 is H or lower alkyl. The invention also provides precursors of formula I, radioactive analogs of formula I, and methods of using the compounds for the identification of 5-HT-3 receptors and the detection and treatment of abnormal conditions associated therewith.

Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D2 receptor in the mammalian brain. These compounds have a specific combination of lipophilicity and dopamine D2 receptor affinity required to attain a required image contrast. The iodinated benzamides identified by the above discovery can be made by reacting a trialkyltin substituted benzamide with an acid in the presence of radioactive iodine which, in turn, is generated by in situ oxidation of an appropriate iodide nuclide salt.

Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D-2 receptor in the mammalian brain. The substituted benzamides and their racemic mixtures or their optically resolved enantiomers can be made by reacting a trialyltin substituted benzamide with an acid in the presence of radioactive iodine, generated by in situ oxidation of an appropriate iodide nuclide salt.

Abstract: Novel therapeutically active compounds of the formula ##STR1## wherein R is a straight or branched alkyl group with 6-18 carbon atoms, R.sup.1 is hydrogen, chlorine, bromine or an alkyl group with 1-3 carbon atoms and R.sup.2 is chlorine, bromine or an alkyl group with 1-3 carbon atoms; or a physiologically acceptable salt or an optical isomer thereof, methods and intermediates for their preparation, pharmaceutical preparations containing them and methods for their therapeutical use.

Abstract: Compounds of the formula ##STR1## wherein R is H or CH.sub.3, n is 1 or 2 and X is F, Cl, Br, I bound in an optional position to the phenyl group, provided that when X is Br it is bound in a position other than the 4 position, processes for their preparation and phrmaceutical preparations, methods of treatment employing such compounds. The compounds are useful for therapeutic treatment of various kinds of depressive conditions.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein X and Y are the same or different and each represents a hydrogen atom, a chloro or a methoxy group, n is an integer 0 or 1 and R.sup.1 and R.sup.2 are the same or different and each representing a hydrogen atom or a methyl group; processes for their preparation; pharmaceutical preparations containing at least one of these compounds and the use thereof in the treatment of depressive states.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof; processes for their preparation; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof as a tranquilizing or neuroleptic agent.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein X and Y are the same or different and each representing a hydrogen atom, a chloro or a methoxy group, n is an integer 0 or 1 and R.sup.1 and R.sup.2 are the same or different and each representing a hydrogen atom or a methyl group; processes for their preparation; pharmaceutical preparations containing at least one of these compounds and the use thereof in the treatment of depressive states.